摘要
目的分析哮喘患者治疗中采用布地奈德吸入剂联合特布他林治疗的临床效果及对肺功能的影响。方法于2017年1月—2019年1月该院收治的100例支气管哮喘患者为研究对象,根据随机、单盲法平均分组,对比组(50例)以特布他林为临床治疗方案,而研究组(50例)以布地奈德+特布他林为治疗方案。观察治疗效果。结果研究组有效率(96.0%)与对比组(82.0%)比较,前者更高,差异有统计学意义(χ^2=5.005,P=0.025)。治疗后,研究组FEV1、FVC及FEV1%指标分别为(1.3±0.5)L、(2.3±0.7)L和(66.3±10.1)%,对比组分别为(1.0±0.4)L、(1.9±0.6)L和(58.3±9.9)%,研究组更优,差异有统计学意义(t=3.313、3.068、4.000,P<0.05)。研究组患者主要临床症状改善时间均比对比组更加提前,差异有统计学意义(P<0.05)。结论布地奈德吸入剂联合特布他林应用在支气管哮喘的治疗中,对患者各项临床症状具有较大的改善作用。
Objective To analyze the clinical effect of budesonide inhalation combined with terbutaline in the treatment of asthma patients and its influence on lung function.Methods 100 patients with bronchial asthma in the hospital from January 2017 to January 2019 were selected.The patients were divided into two groups according to random and single-blind method.The comparison group(50 cases)took terbutaline as the clinical treatment plan,while the study group(50 cases)took budesonide+terbutaline as the treatment plan.Observe the treatment effect.Results The effective rate of the study group(96.0%)was higher than that of the control group(82.0%),the difference was statistically significant(χ^2=5.005,P=0.025).After treatment,the FEV1、FVCand FEV1% indexes of the study group were(1.3±0.5)L,(2.3±0.7)L and(66.3±10.1)%,respectively,and the comparison group were(1.0±0.4)L,(1.9±0.6)L and(58.3±9.9)%,the study group was better,the difference was statistically significant(t=3.313,3.068,4.000,P<0.05).The main clinical symptoms of the patients in the study group improved earlier than the comparison group,the difference was statistically significant(P<0.05).Conclusion The application of budesonide inhalant combined with terbutaline in the treatment of bronchial asthma can greatly improve the clinical symptoms of patients.
作者
李红岩
唐铖
张业清
LI Hong-yan;TANG Cheng;ZHANG Ye-qing(The Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing,Jiangsu Province,210028 China)
出处
《世界复合医学》
2020年第12期154-156,共3页
World Journal of Complex Medicine
